References

Prevalence of excess adiposity by body mass index category among US children and adolescents

10.1001/jamapediatrics.2025.4291 · 2026 · External reference

GLP-1 receptor agonist prescriptions for adolescents with obesity and associated disparities

10.1001/jamapediatrics.2025.5708 · 2026 · External reference

Clinical practice guideline for the evaluation and treatment of children and adolescents with obesity

10.1542/peds.2022-060640 · 2023 · External reference

A randomized, controlled trial of liraglutide for adolescents with obesity

10.1056/nejmoa1916038 · 2020 · External reference

Once-weekly semaglutide in adolescents with obesity

10.1056/nejmoa2208601 · 2022 · External reference

Efficacy and safety of tirzepatide in children and adolescents with type 2 diabetes (SURPASS-PEDS): a randomised, double-blind, placebo-controlled, phase 3 trial

10.1016/s0140-6736(25)01774-x · 2025 · External reference

Liraglutide for children 6 to <12 years of age with obesity - a randomized trial

10.1056/nejmoa2407379 · 2025 · External reference

Unresolved reference

2025 · External reference

Unresolved reference

2025 · External reference

Measuring community vulnerability to natural and anthropogenic hazards: The Centers for Disease Control and Prevention’s Social Vulnerability Index

2018 · External reference

Social vulnerability indices: a scoping review

10.1186/s12889-023-16097-6 · 2023 · External reference